Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold -- Ignore unavailable to you. Want to Upgrade?

To: pull_da_trigger who wrote (608)	11/30/2001 10:30:58 PM
From: Al Collard	Respond to of 4470

Hi P.D.T., Your in with ONC-t @$7.44 for 2,688 shares. Chart for Oncolytics Biotech, Inc: stockcharts.com[l,a]djcanimy[dc][pc20!b50!b100!b200!f][vc60][iUb14!Ll14!La12,26,9!Lp14,3,3!Lc20] From the chart of ONC we can see the stock broke out from the resistance of it's 20EMA, broke through it's 50MA, with force and tested the resistance of it's 100MA. The chart indicators are all bullish and pointing up on average volume. Looks good P.D.T. Good luck with this pick, Al

To: pull_da_trigger who wrote (608)	12/4/2001 12:59:17 PM
From: Al Collard	Respond to of 4470

ONC-t...in the news: Oncolytics completes 28-day Reolysin study Tue 4 Dec 2001 News Release Dr. Matt Coffey reports Oncolytics Biotech has successfully completed its first systemic toxicology study of multiple injections of Reolysin in animals. The toxicology study examined the effects of 28 consecutive days of intravenous administration of Reolysin in Sprague-Dawley rats. These studies were conducted in support of future systemic clinical trials that Oncolytics is currently planning. The results of the studies demonstrated that there were no significant adverse clinical outcomes as a result of the administration of the reovirus at any of the dose levels tested. "This study supports the planned clinical studies examining the efficacy and safety of Reolysin when delivered systemically," said Dr. Matt Coffey, vice-president of product development at Oncolytics. "The successful completion of this study underlies the strategic direction of moving this product from intratumoral clinical studies to systemic trials. Delivering Reolysin systemically will increase the number of cancer indications that this product could potentially treat as well as allowing us to examine the effectiveness of the product against metastatic disease."